Cancer immunology.

By C. Melief, O. Finn. Current Opinion in Immunology, 2011

913 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/9ce21d020cdc54dd73640ddd1d7cfaed0c20677e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

Citations in the corpus

The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis (2011, background): “It has been shown that immune cells can proliferate in vitro in response to tumour-specific antigens, and that the influx of immune cells into a tumour results in the induction of an inflammatory microenvironment (reviewed in Kim et al , 2007; Finn, 2008).”
Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids (2018, neutral): “Treatment failure may be explained at many different levels that include a low number of immunogenic antigens, defective antigen presentation, and/or the expression of alternative immune checkpoint molecules (Blank et al., 2016; Dijkstra et al., 2016; Pitt et al., 2016; Sharma et al., 2017).”
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. (2009, background): “36,37 (3) IL-17–deficient mice exhibit accelerated tumor growth and lung metastasis.”
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…by CTLs, type 1 helper (TH1) CD4+ T lymphocytes and NK cells, escape is accompanied by the near-tocomplete disappearance of the immune infiltrate or by accumulation of cells that inhibit tumor-targeting immune responses, including TREG cells and immunosuppressive myeloid cells (Finn, 2008).”
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma (2016, background): “84 Encouragingly, recent studies had demonstrated that tumor mutational load(4-6), DNA 85 mismatch repair (MMR) deficiency(7), the intensity of CD8+ T cell infiltrates(8, 9) and 86 intratumoral PD-L1 expression(10, 11) have each been proposed as distinct biomarkers of 87 response to anti‐PD-1/PD-L1 ”
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. (2013, background): “…referred to as immunosurveillance) and can grow into clinically manifest tumors only if they lose the immunogenic determinants that make them recognizable by immune effectors (immunoselection) or if they actively inhibit immune responses (immunosuppression) (Finn, 2008; Schreiber et al., 2011).”
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. (2012, background): “By directly targeting specific antigens expressed by cancer cells, anticancer monoclonal antibodies are a well-established class of immunotherapeutic agent; more than a dozen of which have been approved by the Food and Drug Administration as standard treatment of several different cancers, including”
Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment (2017, background): “Our findings may aid in the implementation of immunotherapy approaches (Blank et al., 2016) in a disease type with very limited treatment options.”
Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade (2016, neutral): “The immunophenoscore is similar to the conceptual immunogram that was recently proposed to represent the status of the immune system (Blank et al., 2016).”